Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Byetta Pancreatitis

Byetta Side Effects May Link To Pancreatitis Lawsuits

Byetta | Lawsuits, Lawyers | Side Effects: Necrotizing, Pancreatitis, Acute Pancreatitis, Hemorrhagic Pancreatitis, Bleeding, Tissue Damage

Byetta has been linked to the onset of acute pancreatitis, as well as hemorrhagic and necrotizing pancreatitis. At least two people have died as a result of Byetta-associated pancreatitis. If you or a loved one were diagnosed with pancreatitis while taking Byetta for type 2 diabetes, please contact one of our Byetta pancreatitis lawyers as soon as possible to protect your rights.

Byetta is made by Amylin Pharmaceuticals Inc, and marketed jointly by Amylin and Eli Lilly, Co. The drug was approved by the Food Drug Administration (FDA) in 2005 to help type 2 diabetics better control blood sugar when other drugs were not adequate. The twice-daily injection is a synthetic form of a lizard hormone that boosts the production of insulin.

More than 700,000 patients worldwide have used Byetta since it was launched. While diabetics are more vulnerable to developing pancreatitis than those without the disease, it is becoming apparent that this drug increases that risk. Our Byetta pancreatitis lawyers will work hard to make sure that these companies are held accountable for their negligence.

In August 2008, the FDA said it was working with Amylin to add stronger and more prominent warnings on the product label about the risk of acute hemorrhagic or necrotizing pancreatitis. However, the FDA did not indicate if such warnings would take the form of a black box the agency's most urgent safety alert. Our Byetta pancreatitis lawyer believe that Amylin should have added such a warning much earlier, when the drug's association with pancreatitis became apparent.

FDA Byetta Warnings

Since October 2007, the FDA has issued two warnings regarding Byetta and acute pancreatitis, as well as hemorrhagic and necrotizing pancreatitis. Pancreatitis is an inflammation of the pancreas that can cause bleeding, tissue damage and infection. Severe cases of pancreatitis can lead to the release of toxins and enzymes into the blood stream that can injure the heart, lungs, kidneys or other organs. In some instances, pancreatitis can be fatal.

In October 2007, the FDA issued a health alert after it received 30 reports of Byetta patients who developed acute pancreatitis. Of those, 5 later suffered from kidney failure. Six patients experienced the onset or worsening of symptoms after their dosage of Byetta was increased from 5 milligrams twice daily to 10 milligrams twice daily. And according to the FDA, pancreatitis symptoms in 22 patients subsided or improved once they quit taking Byetta.

Acute pancreatitis comes on suddenly, and is characterized by mild to severe pain in the upper abdomen that may radiate to the back and occasionally to the chest. The pain can be nearly constant for hours or days, and will become worse if a patient drinks alcohol or eats. Bending forward or curling into a fetal position may provide temporary relief. The Byetta pancreatitis lawyers at our firm know how serious and debilitating acute pancreatitis is, and we will make sure that the victims of this dangerous drug receive the compensation they deserve.

At the time of the 2007 alert, the FDA said that Amylin had agreed to include information about acute pancreatitis in the PRECAUTIONS section of the Byetta label. However, as of August 2008, that information still was not included on the Byetta package insert.

In August 2008, the FDA issued its second pancreatitis warning for Byetta. At the time, the agency said that it had received reports of 6 cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta since its October alert. All patients required hospitalization, two patients died and four patients were recovering at time of reporting.Byetta was discontinued in all 6 cases.

Hemorrhagic pancreatitis is inflammation that involves bleeding. Necrotizing pancreatitis occurs when the inflamed pancreas destroys itself. There are no signs or symptoms that distinguish hemorrhagic or necrotizing pancreatitis associated with Byetta from the less severe form of pancreatitis.

The FDA alert said that Byetta should be discontinued if pancreatitis is suspected. The FDA also said doctors should consider antidiabetic therapies other than Byetta in patients with a history of pancreatitis. Patients taking Byetta should seek prompt medical care if they experience unexplained persistent severe abdominal pain which may or may not be accompanied by vomiting.

Legal Help Byetta Pancreatitis Victims

If you or a loved one suffered from acute pancreatitis, necrotizing pancreatitis or hemorrhagic pancreatitis that may have been caused by Byetta, you have valuable legal rights. Please fill out our online form or call 1-800 YOURLAWYER (1-800-968-7529) to discuss your case with an experienced Byetta pancreatitis lawyer.


Byetta PancreatitisRSS Feed

Byetta, Januvia Cancer Risks Debated

Sep 21, 2011 | Parker Waichman LLP
The uncertainty surrounding type 2 diabetes drugs like  Byetta and Januvia have prompted calls for more studies of glucagon-like peptide 1 (GLP-1) therapies.  A recent study has tied Byetta and Januvia to a possible increased risk of pancreatic cancer, but other researchers, along with the drug's manufacturers.GLP-1 therapies mimic a hormone called GLP-1 to stimulate natural insulin production in diabetics.  In addition to Byetta and Januvia, Novo Nordisk's Victoza is also in...

Study Find Januvia, Byetta Associated with Increased Risk of Pancreatitis, Pancreatic Cancer

Sep 19, 2011 | Parker Waichman LLP
Diabetes drugs that lower blood sugar by promoting the action of a gut hormone called glucagon-like peptide 1 (GLP-1) may increase the risks of both pancreatitis and pancreatic cancer, according to a new study published in the journal Gastroenterology.  The study found that Januvia and Byetta, both type 2 diabetes medications, increased the risk of pancreatitis by 6-fold.  Pancreatitis is a known risk-factor for pancreatic cancer.According to a report from EMaxHealth, animal studies...

Byetta, Victoza Raise More Cancer Fears

Sep 13, 2011 | Parker Waichman LLP
A new study is adding to concerns that type 2 drugs like Byetta and Victoza could increase the likelihood that a patient will develop pancreatitis and pancreatic cancer.  The study found that Byetta increases the risk for pancreatits - a known risk factor for pancreatic cancer - by six-fold, according to Bloomberg News.  While Victoza, which was only approved last year, wasn't included in the study, both it and Byetta are injectable medications that belong to the same class of drugs,...

Doctors Reminded of Victoza Thyroid Tumor, Pancreatitis Risks

Jun 14, 2011 | Parker Waichman LLP
It seems many doctors are unaware of the serious side effects that may be associated with the Type II Diabetes drug Victoza.  As a result, Novo Nordisk has sent a letter to doctors reminding them that Victoza may be associated with thyroid tumors and acute pancreatitis.Victoza is very similar to Byetta.  Both are injectables, and both act on glucagon-like-peptide-1 (GLP-1), a hormone in the digestive tract that impacts glucose levels.According to the Novo Nordisk Victoza letter,...

Victoza Report Raises Byetta Safety Questions

Jun 7, 2011 | Parker Waichman LLP
A new report from the Institute for Safe Medicine Practices (ISMP) may raise safety concerns about a new generation of diabetes drugs, including Byetta.  While the group’s new QuarterWatch report discusses another drug called Victoza and pancreatitis, the ISMP raises concerns that similar diabetes medications may also pose an elevated risk of pancreatitis.Both Byetta and Victoza are injectable medications that act on glucagon-like-peptide-1 (GLP-1), a hormone in the digestive tract...

More Byetta Pancreatitis News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo